Delcath Systems, Inc. (NASDAQ:DCTH)’s share price was down 4% during trading on Tuesday . The stock traded as low as $0.10 and last traded at $0.10. Approximately 33,204,597 shares traded hands during trading, a decline of 69% from the average daily volume of 106,796,000 shares. The stock had previously closed at $0.11.

The stock’s market capitalization is $51.57 million. The company’s 50-day moving average is $0.12 and its 200 day moving average is $0.10.

An institutional investor recently raised its position in Delcath Systems stock. Vanguard Group Inc. raised its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 207.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,285,679 shares of the medical device company’s stock after purchasing an additional 866,838 shares during the quarter. Vanguard Group Inc. owned 1.09% of Delcath Systems worth $253,000 at the end of the most recent reporting period. Institutional investors own 7.97% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Delcath Systems, Inc. (DCTH) Shares Down 4%” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/07/delcath-systems-inc-dcth-shares-down-4.html.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.